Characteristics of participants
We recruited 499 CHD patients and 505 healthy controls. There were 317 males and 182 females in the case group, and 323 males and 182 females in the control group. The Chi-square test results indicated that no significant difference in the distribution of gender was found between the case and control groups (P = 0.886) (Table 1). The mean ages of the case and control groups were 61.34 and 60.51, respectively. No significant difference was found in the distribution of mean age between cases and controls in study populations (P = 0.191) (Table 1). There were no significant difference in triglyceride, HDL-C, EO and RDW-CV (P > 0.05) between the patients and controls. However, there were significant differences in some biochemistry and blood test indicators (total protein, albumin, globulin, total bilirubin, direct bilirubin, indirect bilirubin, uric acid, triglyceride, total cholesterol, HDL-C, LDL-C, WBC, NEUT, LYMP, EO, BASO, RBC, hemoglobin, MCV, MCH, RDW, RDW-CV, platelet, plateletcrit) between cases and controls (P < 0.05) (Table 1). Simultaneously, we also found the mean triglyceride and BASO levels in the case group were higher than the clinical reference values and control group, suggesting that these factors may increase the risk of CHD.
Table 1
Characteristics of the study population
Variables | Case | Control | P |
N | Mean ± SD | N | Mean ± SD |
Age (years) | 499 | 61.34 ± 11.69 | 505 | 60.51 ± 8.11 | 0.191 |
Gender (M/F) | 317/182 | --- | 323/182 | --- | 0.886 |
Total protein (g/L) | 485 | 66.42 ± 6.36 | 360 | 71.65 ± 3.79 | < 0.001 |
Albumin (g/L) | 485 | 41.01 ± 4.33 | 362 | 45.58 ± 2.93 | < 0.001 |
Globulin (g/L) | 485 | 25.41 ± 3.3 | 362 | 26.21 ± 3.5 | 0.001 |
Total bilirubin (umol/L) | 485 | 13.87 ± 6.12 | 362 | 16.97 ± 5.86 | < 0.001 |
Direct bilirubin (umol/L) | 485 | 7.76 ± 3.36 | 362 | 4.86 ± 2.01 | < 0.001 |
Indirect bilirubin (umol/L) | 484 | 6.04 ± 3.47 | 361 | 11.80 ± 3.98 | < 0.001 |
Uric acid (umol/L) | 476 | 292.67 ± 87.62 | 361 | 326.17 ± 80.95 | < 0.001 |
Triglyceride (mmol/L) | 470 | 1.78 ± 1.48 | 362 | 1.70 ± 1.18 | 0.418 |
Total cholesterol (mmol/L) | 469 | 4.09 ± 1.15 | 361 | 4.78 ± 1.00 | < 0.001 |
HDL-C (mmol/L) | 470 | 1.13 ± 0.25 | 296 | 1.13 ± 0.25 | 0.862 |
LDL-C (mmol/L) | 470 | 1.92 ± 0.82 | 293 | 2.65 ± 0.76 | < 0.001 |
WBC (*10E9/L) | 491 | 11.67 ± 15.48 | 360 | 5.79 ± 1.48 | < 0.001 |
NEUT (*10E9/L) | 491 | 4.97 ± 3.00 | 360 | 3.36 ± 1.12 | < 0.001 |
LYMP (*10E10/L) | 491 | 1.65 ± 0.79 | 360 | 1.85 ± 0.61 | < 0.001 |
EO (*10E9/L) | 433 | 0.14 ± 0.33 | 359 | 0.14 ± 0.15 | 0.814 |
BASO (*10E9/L) | 414 | 0.42 ± 1.31 | 359 | 0.03 ± 0.02 | < 0.001 |
RBC (10E12/L) | 455 | 4.73 ± 0.66 | 360 | 4.83 ± 0.41 | 0.006 |
Hemoglobin (g/L) | 452 | 140.11 ± 17.96 | 360 | 148.53 ± 14.09 | < 0.001 |
MCV (fL) | 455 | 92.27 ± 6.19 | 360 | 90.99 ± 4.25 | 0.001 |
MCH (pg) | 455 | 29.57 ± 2.66 | 359 | 30.76 ± 1.66 | < 0.001 |
RDW (fL) | 454 | 43.79 ± 4.41 | 359 | 44.47 ± 3.56 | 0.015 |
RDW-CV (%) | 455 | 13.29 ± 1.19 | 359 | 13.43 ± 1.04 | 0.064 |
Platelet (*10E9/L) | 455 | 182.43 ± 60.35 | 359 | 207.51 ± 56.19 | < 0.001 |
Plateletcrit (%) | 440 | 0.21 ± 0.07 | 344 | 0.23 ± 0.05 | < 0.001 |
F: female; M: male; SD: standard deviation; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; WBC: white blood cell count; NEUT: neutrophil absolute value; LYMP: Lymphocyte absolute value; EO: eosinophils absolute value; BASO: basophilic absolute value; RBC: red blood cell count; MCV: erythrocyte mean corpuscular volume; MCH: mean corpuscular hemoglobin; RDW: red blood cell distribution width; RDW-CV: red blood cell distribution width coefficient of variation |
P < 0.05 indicates statistical significance. |
Overall analysis of NPAS4 polymorphisms and CHD risk
The five SNPs (rs117770654, rs117957381, rs12785321, rs117186164, and rs4466842) in NPAS4 were successfully genotyped, and the call rate of genotyping was more than 95%. The genotypes distributions of all SNPs were in line with HWE in both CHD patients and controls (P > 0.05, Table 2). We found that the allele C frequency of the rs4466842 in NPAS4 in CHD patients was higher than the healthy controls (0.442 vs. 0.389, P = 0.016). The rs4466842 was related to an increased risk of CHD (OR = 1.25, 95% CI: 1.04–1.49). However, there was no significant association between other four SNPs and CHD risk.
Table 2
Alleles frequencies distribution and association with CHD risk
SNP–ID | Chr | Position | Role | Alleles A/B | MAF | HWE–p | OR (95% CI) | p |
Case | Control |
rs117770654 | 11 | 66410723 | Intron | A/G | 0.036 | 0.035 | 0.457 | 1.04 (0.65–1.67) | 0.863 |
rs117957381 | 11 | 66411414 | Intron | A/G | 0.065 | 0.061 | 0.702 | 1.08 (0.76–1.56) | 0.662 |
rs12785321 | 11 | 66412265 | Intron | A/C | 0.445 | 0.408 | 0.780 | 1.16 (0.97–1.39) | 0.097 |
rs117186164 | 11 | 66412318 | Intron | A/G | 0.059 | 0.045 | 1.000 | 1.35 (0.90–2.01) | 0.141 |
rs4466842 | 11 | 66415549 | Intron | C/T | 0.442 | 0.389 | 0.851 | 1.25 (1.04–1.49) | 0.016 |
CHD: coronary heart disease; SNP: single nucleotide polymorphism; Chr: chromosome; MAF: minor allele frequency; HWE: hardy-Weinberg equilibrium; OR: odds ratio; CI: confidence interval. |
p < 0.05 indicates statistical significance. |
We performed genetic models analysis to explore the genotype distributions and the correlation between SNPs and CHD risk before and after adjusted with age and gender, as shown in Table 3. The results indicated that individual carrying the TT genotype of rs4466842 in NPAS4 was correlated with an increased CHD risk, compared with the CC genotype (OR = 1.54, 95% CI: 1.06–2.22, P = 0.022; adjusted OR = 1.56, 95% CI: 1.08–2.25, P = 0.018). We found that the rs7318578 was related to an increased with CHD risk in the dominant model (TT-TC vs. CC: OR = 1.34, 95% CI: 1.03–1.74, P = 4.70E-10; adjusted OR = 1.35, 95% CI: 1.04–1.75, P = 0.027) and the additive model (OR = 1.25, 95% CI: 1.04–1.49, P = 0.016; adjusted OR = 1.25, 95% CI: 1.05–1.50, P = 0.013). However, no significant correlation was found between other four SNPs and CHD risk.
Table 3
Genotypes frequencies distribution and association with CHD risk
SNP-ID | Model | Genotype | Case (%) | Control (%) | OR (95% CI) | p | adjust OR (95% CI) | p |
rs117770654 | Codominant | GG | 463 (92.8) | 471 (93.3) | 1 | | 1 | |
| | AG | 36 (7.2) | 33 (6.5) | 1.11 (0.68–1.81) | 0.677 | 1.10 (0.67–1.79) | 0.708 |
| | AA | 0 (0) | 1 (0.2) | -- | | -- | |
| Dominant | GG | 463 (92.8) | 471 (93.3) | 1 | | 1 | |
| | AA-AG | 36 (7.2) | 34 (6.7) | 1.08 (0.66–1.75) | 0.765 | 1.07 (0.66–1.74) | 0.796 |
| Recessive | AG-GG | 499 (100) | 504 (99.8) | -- | | -- | |
| | AA | 0 (0) | 1 (0.2) | -- | -- | -- | -- |
| Additive | -- | -- | -- | 1.04 (0.65–1.68) | 0.863 | 1.03 (0.64–1.66) | 0.895 |
rs117957381 | Codominant | AA | 436 (87.6) | 445 (88.3) | 1 | | 1 | |
| | GA | 59 (11.8) | 57 (11.3) | 1.06 (0.72–1.56) | 0.781 | 1.05 (0.71–1.55) | 0.812 |
| | GG | 3 (0.6) | 2 (0.4) | 1.53 (0.25–9.21) | 0.642 | 1.46 (0.24–8.80) | 0.680 |
| Dominant | AA | 436 (87.6) | 445 (88.3) | 1 | | 1 | |
| | GG-GA | 62 (12.4) | 59 (11.7) | 1.07 (0.73–1.57) | 0.718 | 1.06 (0.73–1.56) | 0.756 |
| Recessive | GA-AA | 495 (99.4) | 502 (99.6) | 1 | | 1 | |
| | GG | 3 (0.6) | 2 (0.4) | 1.52 (0.25–9.14) | 0.647 | 1.45 (0.24–8.75) | 0.685 |
| Additive | -- | -- | -- | 1.08 (0.76–1.55) | 0.665 | 1.07 (0.75–1.53) | 0.707 |
rs12785321 | Codominant | CC | 156 (31.3) | 175 (35.4) | 1 | | 1 | |
| | AC | 242 (48.5) | 236 (47.7) | 1.15 (0.87–1.52) | 0.328 | 1.16 (0.87–1.53) | 0.308 |
| | AA | 101 (20.2) | 84 (17) | 1.35 (0.94–1.94) | 0.104 | 1.37 (0.96–1.97) | 0.086 |
| Dominant | CC | 156 (31.3) | 175 (35.4) | 1 | | 1 | |
| | AA-AC | 343 (68.7) | 320 (64.6) | 1.20 (0.92–1.57) | 0.171 | 1.21 (0.93–1.58) | 0.152 |
| Recessive | AC-CC | 398 (79.8) | 411 (83) | 1 | | 1 | |
| | AA | 101 (20.2) | 84 (17) | 1.24 (0.90–1.71) | 0.186 | 1.26 (0.91–1.74) | 0.160 |
| Additive | -- | -- | -- | 1.16 (0.97–1.38) | 0.100 | 1.17 (0.98–1.40) | 0.083 |
rs117186164 | Codominant | AA | 445 (89.2) | 461 (91.3) | 1 | | 1 | |
| | GA | 49 (9.8) | 43 (8.5) | 1.18 (0.77–1.81) | 0.449 | 1.18 (0.77–1.82) | 0.444 |
| | GG | 5 (1) | 1 (0.2) | 5.18 (0.6-44.51) | 0.134 | 5.66 (0.65–48.89) | 0.115 |
| Dominant | AA | 445 (89.2) | 461 (91.3) | 1 | | 1 | |
| | GG-GA | 54 (10.8) | 44 (8.7) | 1.27 (0.84–1.93) | 0.261 | 1.28 (0.84–1.95) | 0.250 |
| Recessive | GA-AA | 494 (99) | 504 (99.8) | 1 | | 1 | |
| | GG | 5 (1) | 1 (0.2) | 5.1 (0.59–43.82) | 0.138 | 5.57 (0.64–48.09) | 0.119 |
| Additive | -- | -- | -- | 1.32 (0.90–1.95) | 0.156 | 1.34 (0.91–1.97) | 0.142 |
rs4466842 | Codominant | CC | 155 (31.1) | 189 (37.6) | 1 | | 1 | |
| | TC | 247 (49.5) | 237 (47.1) | 1.27 (0.96–1.68) | 0.090 | 1.28 (0.97–1.68) | 0.086 |
| | TT | 97 (19.4) | 77 (15.3) | 1.54 (1.06–2.22) | 0.022 | 1.56 (1.08–2.25) | 0.018 |
| Dominant | CC | 155 (31.1) | 189 (37.6) | 1 | | 1 | |
| | TT-TC | 344 (68.9) | 314 (62.4) | 1.34 (1.03–1.74) | 0.030 | 1.35 (1.04–1.75) | 0.027 |
| Recessive | TC-CC | 402 (80.6) | 426 (84.7) | 1 | | 1 | |
| | TT | 97 (19.4) | 77 (15.3) | 1.34 (0.96–1.86) | 0.085 | 1.35 (0.97–1.88) | 0.073 |
| Additive | -- | -- | -- | 1.25 (1.04–1.49) | 0.016 | 1.25 (1.05–1.50) | 0.013 |
CHD: coronary heart disease; SNP: single nucleotide polymorphism; OR: odds ratio; CI: confidence interval. |
Adjust OR (95%CI) were calculated by logistic regression analysis with adjustments for age and gender. |
p < 0.05 indicates statistical significance. |
Subgroup analysis of NPAS4 polymorphisms and CHD risk
When stratifying by gender, we found that rs117186164 was significantly correlated with an increased risk of CHD in the allele (G vs. A: OR = 1.85, 95% CI: 1.09–3.16, P = 0.022), dominant (GG-GA vs. AA: OR = 1.81, 95% CI: 1.04–3.14, P = 0.036), and additive model (OR = 1.85, 95% CI: 1.09–3.15, P = 0.024) after adjusted with age in the males (Table 4). The rs4466842 was significantly correlated with an increased risk of CHD in the allele (T vs. C: OR = 1.37, 95% CI: 1.09–1.71, P = 0.006), codominant (TC vs. CC: OR = 1.42, 95% CI: 1.00–2.02, P = 0.048; TT vs. CC: OR = 1.83, 95% CI: 1.16–2.89, P = 0.009) dominant (TT-TC vs. CC: OR = 1.53, 95% CI: 1.10–2.12, P = 0.012), and additive model (OR = 1.36, 95% CI: 1.09–1.70, P = 0.006) after adjusted with age in the males (Table 4). However, no association was found between SNPs in NPAS4 and CHD risk in females.
Table 4
Association of rs117186164 and rs4466842 with CHD risk stratified by gender
SNP-ID | Model | Genotype | Male | Female |
Case (%) | Control (%) | OR (95% CI) | P | Case (%) | Control (%) | OR (95% CI) | P |
rs117186164 | Allele | A | 597 (93.9) | 624 (96.6) | 1 | | 342 (94.5) | 341 (93.7) | 1 | |
| | G | 39 (6.1) | 22 (3.4) | 1.85 (1.09–3.16) | 0.022 | 20 (5.5) | 23 (6.3) | 0.87 (0.47–1.61) | 0.651 |
| Codominant | AA | 281 (88.4) | 301 (93.2) | 1 | | 164 (90.6) | 160 (87.9) | 1 | |
| | GA | 35 (11) | 22 (6.8) | 1.70 (0.97–2.97) | 0.063 | 14 (7.7) | 21 (11.5) | 0.66 (0.32–1.34) | 0.244 |
| | GG | 2 (0.6) | 0 (0) | -- | -- | 3 (1.7) | 1 (0.5) | 3.03 (0.31–29.58) | 0.341 |
| Dominant | AA | 281 (88.4) | 301 (93.2) | 1 | | 164 (90.6) | 160 (87.9) | 1 | |
| | GG-GA | 37 (11.6) | 22 (6.8) | 1.81 (1.04–3.14) | 0.036 | 17 (9.4) | 22 (12.1) | 0.76 (0.39–1.49) | 0.424 |
| Recessive | GA-AA | 316 (99.4) | 323 (100) | -- | | 178 (98.3) | 181 (99.5) | 1 | |
| | GG | 2 (0.6) | 0 (0) | -- | -- | 3 (1.7) | 1 (0.5) | 3.17 (0.32–30.91) | 0.321 |
| Additive | -- | -- | -- | 1.85 (1.09–3.15) | 0.024 | -- | -- | 0.89 (0.50–1.59) | 0.695 |
rs4466842 | Allele | C | 344 (54.1) | 396 (61.7) | 1 | | 213 (58.8) | 219 (60.2) | 1 | |
| | T | 292 (45.9) | 246 (38.3) | 1.37 (1.09–1.71) | 0.006 | 149 (41.2) | 145 (39.8) | 1.06 (0.79–1.42) | 0.716 |
| Codominant | CC | 94 (29.6) | 125 (38.9) | 1 | | 61 (33.7) | 64 (35.2) | 1 | |
| | TC | 156 (49.1) | 146 (45.5) | 1.42 (1.00-2.02) | 0.048 | 91 (50.3) | 91 (50) | 1.06 (0.67–1.66) | 0.819 |
| | TT | 68 (21.4) | 50 (15.6) | 1.83 (1.16–2.89) | 0.009 | 29 (16) | 27 (14.8) | 1.14 (0.61–2.15) | 0.683 |
| Dominant | CC | 94 (29.6) | 125 (38.9) | 1 | | 61 (33.7) | 64 (35.2) | 1 | |
| | TT-TC | 224 (70.4) | 196 (61.1) | 1.53 (1.10–2.12) | 0.012 | 120 (66.3) | 118 (64.8) | 1.07 (0.70–1.66) | 0.747 |
| Recessive | TC-CC | 250 (78.6) | 271 (84.4) | 1 | | 152 (84) | 155 (85.2) | 1 | |
| | TT | 68 (21.4) | 50 (15.6) | 1.49 (1.00-2.24) | 0.053 | 29 (16) | 27 (14.8) | 1.11 (0.62–1.96) | 0.731 |
| Additive | -- | -- | -- | 1.36 (1.09–1.70) | 0.006 | -- | -- | 1.07 (0.79–1.44) | 0.683 |
CHD: coronary heart disease; SNP: single nucleotide polymorphism; OR: odds ratio; CI: confidence interval. OR (95%CI) were calculated by logistic regression analysis with adjustments for age. P < 0.05 indicates statistical significance. |
The subgroup analysis was conducted based on mean age revealed that rs12785321 was significantly correlated with an increased risk of CHD in the allele (A vs. C: OR = 1.40, 95% CI: 1.06–1.84, P = 0.016), codominant (AC vs. CC: OR = 1.65, 95% CI: 1.05–2.58, P = 0.031; AA vs. CC: OR = 1.94, 95% CI: 1.09–3.44, P = 0.024), dominant (AA-AC vs. CC: OR = 1.72, 95% CI: 1.13–2.64, P = 0.012), and additive model (OR = 1.42, 95% CI: 1.07–1.89, P = 0.014) after adjusted with gender and age in the age ≤ 60 years old population (Table 5). The rs4466842 was also found to be significantly correlated with an increased risk of CHD in the allele (OR = 1.48, 95% CI: 1.12–1.94, P = 0.005), codominant (TT vs. CC: OR = 1.81, 95% CI: 1.03–3.19, P = 0.040), and additive model (OR = 1.34, 95% CI: 1.02–1.78, P = 0.038) after adjusted with gender and age in the age ≤ 60 years old population (Table 5). These results suggested that gender and age are important factors that influence the risk of CHD.
Table 5
Association of rs12785321 and rs4466842 with CHD risk stratified by age
SNP-ID | Model | Genotype | Age > 60 years old | Age ≤ 60 years old |
Case (%) | Control (%) | OR (95% CI) | P | Case (%) | Control (%) | OR (95% CI) | P |
rs12785321 | Allele | C | 316 (58.5) | 350 (58.5) | 1 | | 238 (52) | 236 (60.2) | 1 | |
| | A | 224 (41.5) | 248 (41.5) | 1.00 (0.79–1.27) | 0.997 | 220 (48) | 156 (39.8) | 1.40 (1.06–1.84) | 0.016 |
| Codominant | CC | 92 (34.1) | 102 (34.1) | 1 | | 64 (27.9) | 73 (37.2) | 1 | |
| | AC | 132 (48.9) | 146 (48.8) | 1.02 (0.69–1.50) | 0.932 | 110 (48) | 90 (45.9) | 1.65 (1.05–2.58) | 0.031 |
| | AA | 46 (17) | 51 (17.1) | 1.26 (0.74–2.13) | 0.396 | 55 (24) | 33 (16.8) | 1.94 (1.09–3.44) | 0.024 |
| Dominant | CC | 92 (34.1) | 102 (34.1) | 1 | | 64 (27.9) | 73 (37.2) | 1 | |
| | AA-AC | 178 (65.9) | 197 (65.9) | 1.07 (0.74–1.54) | 0.713 | 165 (72.1) | 123 (62.8) | 1.72 (1.13–2.64) | 0.012 |
| Recessive | AC-CC | 224 (83) | 248 (82.9) | 1 | | 174 (76) | 163 (83.2) | 1 | |
| | AA | 46 (17) | 51 (17.1) | 1.24 (0.77–2.01) | 0.370 | 55 (24) | 33 (16.8) | 1.44 (0.87–2.40) | 0.156 |
| Additive | -- | -- | -- | 1.10 (0.85–1.42) | 0.465 | -- | -- | 1.42 (1.07–1.89) | 0.014 |
rs4466842 | Allele | C | 318 (58.9) | 372 (60.8) | 1 | | 239 (52.2) | 243 (61.7) | 1 | |
| | T | 222 (41.1) | 240 (39.2) | 1.08 (0.85–1.37) | 0.512 | 219 (47.8) | 151 (38.3) | 1.48 (1.12–1.94) | 0.005 |
| Codominant | CC | 94 (34.8) | 111 (36.3) | 1 | | 61 (26.6) | 78 (39.6) | 1 | |
| | TC | 130 (48.1) | 150 (49) | 1.14 (0.77–1.69) | 0.515 | 117 (51.1) | 87 (44.2) | 1.34 (0.85–2.10) | 0.210 |
| | TT | 46 (17) | 45 (14.7) | 1.04 (0.62–1.75) | 0.887 | 51 (22.3) | 32 (16.2) | 1.81 (1.03–3.19) | 0.040 |
| Dominant | CC | 94 (34.8) | 111 (36.3) | 1 | | 61 (26.6) | 78 (39.6) | 1 | |
| | TT-TC | 176 (65.2) | 195 (63.7) | 1.11 (0.77–1.62) | 0.574 | 168 (73.4) | 119 (60.4) | 1.46 (0.96–2.24) | 0.079 |
| Recessive | TC-CC | 224 (83) | 261 (85.3) | 1 | | 178 (77.7) | 165 (83.8) | 1 | |
| | TT | 46 (17) | 45 (14.7) | 0.96 (0.60–1.53) | 0.867 | 51 (22.3) | 32 (16.2) | 1.52 (0.92–2.51) | 0.098 |
| Additive | -- | -- | -- | 1.04 (0.81–1.34) | 0.770 | -- | -- | 1.34 (1.02–1.78) | 0.038 |
CHD: coronary heart disease; SNP: single nucleotide polymorphism; OR: odds ratio; CI: confidence interval. OR (95%CI) were calculated by logistic regression analysis with adjustments for age. P < 0.05 indicates statistical significance. |
LD and haplotype analysis
Linkage analysis indicated that the five SNPs in NPAS4 clustered two haplotype blocks, block 1: rs117957381 and rs12785321; block 2: rs117186164 and rs4466842, as shown in Fig. 1. Haplotype analysis results found that the haplotype AC (rs117186164 and rs4466842) was correlated with an increased CHD risk before and after adjusting by age and gender (OR = 1.25, 95% CI: 1.04–1.49, P = 0.016; adjusted OR = 1.25, 95% CI: 1.05–1.50, P = 0.013) (Table 6).
Table 6
Association between haplotypes in NPAS4 and CHD risk
SNPs-ID | Haplotype | Case-Fre | Control-Fre | OR (95% CI) | p | adjust OR (95% CI) | p |
rs117957381|rs12785321 | AA | 0.444 | 0.408 | 1.16 (0.97–1.38) | 0.109 | 1.17 (0.98–1.39) | 0.090 |
| GC | 0.065 | 0.060 | 1.10 (0.77–1.57) | 0.614 | 1.09 (0.76–1.56) | 0.653 |
| AC | 0.509 | 0.468 | 1.18 (0.99–1.41) | 0.066 | 1.19 (0.99–1.42) | 0.057 |
rs117186164|rs4466842 | GT | 0.059 | 0.045 | 1.32 (0.90–1.94) | 0.162 | 1.33 (0.90–1.96) | 0.147 |
| AT | 0.383 | 0.344 | 1.18 (0.98–1.42) | 0.073 | 1.19 (0.99–1.42) | 0.066 |
| AC | 0.442 | 0.389 | 1.25 (1.04–1.49) | 0.016 | 1.25 (1.05–1.50) | 0.013 |
CHD: coronary heart disease; SNP: Single nucleotide polymorphism; Fre: frequency; OR: odds ratio; 95% CI: 95% confidence interval |
Adjust OR and 95% CI were calculated using logistic regression adjusted with age and gender. |
P < 0.05 indicates statistical significance. |